BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

532039

ZENOTECH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ZENOTECH LABORATORIES LTD. Share Price Update

As of the latest trading session, ZENOTECH LABORATORIES LTD. share price is currently at ₹ 55.3, which is down by ₹ -1.68 from its previous closing. Today, the stock has fluctuated between ₹ 54.70 and ₹ 56.90. Over the past year, ZENOTECH LABORATORIES LTD. has achieved a return of -17.31 %. In the last month alone, the return has been 6.64 %. Read More...

ZENOTECH LABORATORIES LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    338.40

  • P/E Ratio (TTM)

    60.27

  • Beta

    0.70

  • Book Value / share

    15.75

  • Return on equity

    3.07%

  • EPS (TTM)

    0.75

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    1.23

info icon alternate text

ZENOTECH LABORATORIES LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 11.11
Operating Expense 9.39
Net Profit 1.23
Net Profit Margin (%) 11.07
Earnings Per Share (EPS) 0.20
EBITDA 4.92
Effective Tax Rate (%) 61.44
Particulars DEC 2024 (Values in Cr)
Revenue 10.22
Operating Expense 9.13
Net Profit 1.69
Net Profit Margin (%) 16.53
Earnings Per Share (EPS) 0.28
EBITDA 4.87
Effective Tax Rate (%) 45.65
Particulars SEP 2024 (Values in Cr)
Revenue 8.75
Operating Expense 9.11
Net Profit 1.35
Net Profit Margin (%) 15.42
Earnings Per Share (EPS) 0.22
EBITDA 4.10
Effective Tax Rate (%) 42.55
Particulars JUN 2024 (Values in Cr)
Revenue 8.89
Operating Expense 8.20
Net Profit 1.29
Net Profit Margin (%) 14.51
Earnings Per Share (EPS) 0.21
EBITDA 3.78
Effective Tax Rate (%) 37.07
Particulars MAR 2024 (Values in Cr)
Revenue 8.09
Operating Expense 8.06
Net Profit 0.66
Net Profit Margin (%) 8.15
Earnings Per Share (EPS) 0.11
EBITDA 3.10
Effective Tax Rate (%) 51.82
Particulars MAR 2025 (Values in Cr)
Revenue 38.98
Operating Expense 35.83
Net Profit 5.61
Net Profit Margin (%) 14.39
Earnings Per Share (EPS) 0.92
EBITDA 17.65
Effective Tax Rate (%) 47.52
Particulars MAR 2024 (Values in Cr)
Revenue 36.76
Operating Expense 30.70
Net Profit 8.30
Net Profit Margin (%) 22.57
Earnings Per Share (EPS) 1.36
EBITDA 18.23
Effective Tax Rate (%) 25.49
Particulars MAR 2023 (Values in Cr)
Revenue 38.35
Operating Expense 29.00
Net Profit 11.59
Net Profit Margin (%) 30.22
Earnings Per Share (EPS) 1.90
EBITDA 21.78
Effective Tax Rate (%) 20.13
Particulars MAR 2022 (Values in Cr)
Revenue 32.49
Operating Expense 27.29
Net Profit 22.18
Net Profit Margin (%) 68.26
Earnings Per Share (EPS) 3.63
EBITDA 18.09
Effective Tax Rate (%) -123.93
Particulars MAR 2021 (Values in Cr)
Revenue 19.37
Operating Expense 24.07
Net Profit -1.22
Net Profit Margin (%) -6.29
Earnings Per Share (EPS) -0.20
EBITDA 6.79
Effective Tax Rate (%) 0.00
Particulars MAR 2010 (Values in Cr)
Book Value / Share 28.01
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.13
EBITDA Margin -105.78
Particulars MAR 2009 (Values in Cr)
Book Value / Share 31.55
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.15
EBITDA Margin -198.17
Particulars MAR 2008 (Values in Cr)
Book Value / Share 36.79
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.30
EBITDA Margin -89.96
Particulars MAR 2007 (Values in Cr)
Book Value / Share 18.80
ROE % 3.92
ROCE % 1.59
Total Debt to Total Equity 0.77
EBITDA Margin 22.66
Particulars MAR 2006 (Values in Cr)
Book Value / Share 13.61
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.97
EBITDA Margin -18.41
Particulars MAR 2024 (Values in Cr)
Book Value / Share 14.84
ROE % 3.07
ROCE % 4.09
Total Debt to Total Equity 0.00
EBITDA Margin 44.65
Particulars MAR 2023 (Values in Cr)
Book Value / Share 13.48
ROE % 4.28
ROCE % 5.31
Total Debt to Total Equity 0.04
EBITDA Margin 51.37
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.57
ROE % 13.91
ROCE % 6.37
Total Debt to Total Equity 0.22
EBITDA Margin 49.47
Particulars MAR 2021 (Values in Cr)
Book Value / Share 7.93
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.43
EBITDA Margin 30.24
Particulars MAR 2020 (Values in Cr)
Book Value / Share 8.13
ROE % 2.85
ROCE % 3.01
Total Debt to Total Equity 0.47
EBITDA Margin 39.01
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 19.68
Total Assets 106.20
Total Liabilities 106.20
Total Equity 90.54
Share Outstanding 61030568
Price to Book Ratio 3.98
Return on Assets (%) 7.81
Return on Capital (%) 9.17
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 11.14
Total Assets 100.87
Total Liabilities 100.87
Total Equity 82.27
Share Outstanding 61030568
Price to Book Ratio 3.49
Return on Assets (%) 11.48
Return on Capital (%) 14.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.41
Total Assets 94.08
Total Liabilities 94.08
Total Equity 70.64
Share Outstanding 61030568
Price to Book Ratio 4.35
Return on Assets (%) 23.57
Return on Capital (%) 28.94
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.45
Total Assets 85.84
Total Liabilities 85.84
Total Equity 48.40
Share Outstanding 61030568
Price to Book Ratio 4.41
Return on Assets (%) -1.41
Return on Capital (%) -1.76
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.12
Total Assets 85.55
Total Liabilities 85.55
Total Equity 49.62
Share Outstanding 61030568
Price to Book Ratio 1.81
Return on Assets (%) 12.59
Return on Capital (%) 15.78
Particulars MAR 2024 (Values in Cr)
Net Income 11.14
Cash from Operations 12.89
Cash from Investing -21.15
Cash from Financing 0.00
Net change in Cash -9.33
Free Cash Flow 17.12
Particulars MAR 2023 (Values in Cr)
Net Income 14.50
Cash from Operations 21.85
Cash from Investing -5.82
Cash from Financing -6.11
Net change in Cash 8.72
Free Cash Flow 28.08
Particulars MAR 2022 (Values in Cr)
Net Income 9.90
Cash from Operations 18.67
Cash from Investing -1.83
Cash from Financing -15.87
Net change in Cash -0.04
Free Cash Flow 20.60
Particulars MAR 2021 (Values in Cr)
Net Income -1.21
Cash from Operations 5.85
Cash from Investing -4.81
Cash from Financing 0.45
Net change in Cash 1.37
Free Cash Flow 10.76
Particulars MAR 2020 (Values in Cr)
Net Income 10.77
Cash from Operations 11.66
Cash from Investing -20.79
Cash from Financing -2.70
Net change in Cash -12.11
Free Cash Flow 33.40
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2904.45 57.61 29.41 49203.14 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

ZENOTECH LABORATORIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
55.45 -2.68 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 57.20
  • 26 Days 58.10
  • 10 Days 58.10
  • 50 Days 58.60
  • 12 Days 58.20
  • 100 Days 61.90
  • 20 Days 58.20
  • 200 Days 65.20
57.45 PIVOT

First Support

56.13

First Resistance

58.29

Second Support

55.29

Second Resistance

59.61

Third Support

53.97

Third Resistance

60.45

RSI

46.03

ADX

25.70

MACD

0.45

Williams % R

-92.37

Commodity Channel Index (CCI)

-35.49

Date

2025-04-29

Week

11077.00

Same Day

10084.00

Month

13978.00

1 Year

0.70

3 Year

0.74

Over 1 Month

6.64%

down

Over 1 Year

-17.31%

down

Over 3 Months

-6.84%

down

Over 3 Years

-6.11%

down

Over 6 Months

-26.96%

down

Over 5 Years

22.73%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ZENOTECH LABORATORIES LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
31.15%
Promoter Holdings
68.84%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Sun Pharmaceutical Industries Limited 4.2014578E7 (68.84%) Shareholding of Promoter and Promoter Group
Padmasree Chigurupati 3209982.0 (5.26%) Public Shareholding
Pat Financial Consultants Private Limited 2426000.0 (3.98%) Public Shareholding
Dr. Jayaram Chigurupati 2192632.0 (3.59%) Public Shareholding
Minal Bharat Patel 1050746.0 (1.72%) Public Shareholding
Zenotech Llc 692791.0 (1.14%) Public Shareholding

News

Left Arrow
Right Arrow

ZENOTECH LABORATORIES LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ZENOTECH LABORATORIES LTD. Share Price

Zenotech Laboratories Limited (Formerly Sunline Technologies Limited) was established in June, 1989 and changed to its present name effective on August 9, 2004. The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology.

During financial year 2004-05, the Hon'ble High Court of Andhra Pradesh sanctioned the Scheme of Amalgamation with M/s. Zenotech Technologies Limited with effect from November 1st , 2003. The Company had issued 91,82,500 equity shares to erstwhile shareholders of M/s. Zenotech Laboratories Pvt. Ltd.

M/s, Credence Pharmaceuticals Limited and M/s, Hemarus Healthcare Private Limited were merged with the Company, on May 2, 2006 through Scheme of Amalgamation, effective from October 1, 2005. 15 generic chemical oncology products were launched by the Company in India. Besides, the Company launched its anesthesia range of products during 2006.

Consequent to the consummation of the merger of Ranbaxy Laboratories Limited into SPIL on March 24, 2015, SPIL indirectly acquired 46.84 percent of the voting rights held by Ranbaxy in, and control over the Company and became Promoter of the Company along with Daiichi Sankyo Company Limited and resultant, the Open Offer concluded in August 2015.

The Company started production from its newly commissioned Depot Injectable facility in FY 2019-20. It renovated its Biotech API manufacturing facility and the same was leased to Sun Pharmaceutical Industries Limited, for their R&D activities effective from July, 2021.

Parent organization Sun Pharma
NSE symbol [-]
Founded 1989
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Zenotech Laboratories Ltd?

Answer Field

The share price of Zenotech Laboratories Ltd for NSE is ₹ 0.00 and for BSE is ₹ 55.45.

What is the Market Cap of Zenotech Laboratories Ltd?

Answer Field

The market cap of Zenotech Laboratories Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 3,38.40 Cr. as of now.

What is the 52 Week High and Low of Zenotech Laboratories Ltd?

Answer Field

The 52 Week High and Low of Zenotech Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 107.79 and ₹ 51.00.

How to Buy Zenotech Laboratories Ltd share?

Answer Field

You can trade in Zenotech Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Zenotech Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -19.21%.

What is the Current Share Price of Zenotech Laboratories Ltd?

Answer Field

Zenotech Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 55.45 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Zenotech Laboratories Ltd Share?

Answer Field

The market cap of Zenotech Laboratories Ltd for NSE ₹ 0.0 & for BSE ₹ 3,38.40 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Zenotech Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Zenotech Laboratories Ltd share is 60.27.

What is the PB ratio of Zenotech Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Zenotech Laboratories Ltd share is 15.75.

How to Buy Zenotech Laboratories Ltd Share?

Answer Field

You can trade in Zenotech Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Zenotech Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Zenotech Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Zenotech Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|